Key result
Antibody-mediated targeting of platelet CLEC-2 induces receptor downregulation and thrombocytopenia, impacting its potential therapeutic utility as an antithrombotic therapy.
Understanding the mechanisms of CLEC-2 downregulation is important because targeting it may offer antithrombotic therapeutic utility if thrombocytopenia can be avoided.
In this issue of Blood, Lorenz et al elucidate the mechanisms by which antibody-mediated targeting of platelet C-type lectinlike receptor 2 (CLEC-2) induces receptor downregulation and thrombocytopenia. This information is important because antibody-mediated targeting of CLEC-2 may have therapeutic utility as antithrombotic therapy, especially if thrombocytopenia can be avoided.(1)
No takes yet. Share an insight, caveat, or question.
Debra K. Newman (2015) studied this question. Antibody-mediated targeting of platelet CLEC-2 induces receptor downregulation and thrombocytopenia, impacting its potential therapeutic utility as an antithrombotic therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: